Open menu

Nanotechnology General News

The latest news from academia, regulators
research labs and other things of interest

Posted: February 12, 2008

Arrowhead Announces the Appointment of Dr. Chad Mirkin to Its New Board of Advisors

(Nanowerk News) Arrowhead Research Corporation (Nasdaq:ARWR) announced the appointment of Dr. Chad Mirkin to its newly established Board of Scientific Strategy. He is one of the world’s most renowned nanoscientists whose research accomplishments are complemented by his deep experience translating great science into successful companies. Dr. Mirkin will serve as a Director of Scientific Strategy and join Dr. Mauro Ferrari on Arrowhead’s new advisory board. Together, they will be key contributors to Arrowhead’s operations and strategic plan. Dr. Mirkin’s appointment significantly expands Arrowhead’s “mindshare” within nanotechnology. By bringing the world’s most innovative and respected nanoscientists into its efficient commercialization model, Arrowhead is increasingly able to control the major commercial advancements in nanotechnology. As such, Dr. Mirkin is critical to Arrowhead’s positioning at the center of nanotechnology commercialization.
“Dr. Mirkin is clearly one of the most accomplished and creative nanoscientists in the world, and we are thrilled to have him on our team,” said Arrowhead CEO Chris Anzalone. “His experience conducting world-changing research and building successful nanotechnology companies is a perfect fit for us.”
“I am very excited to be part of the Arrowhead team. Arrowhead has a collection of world-changing technologies and a sound strategy to commercialize them through start-up enterprises,” said Dr. Mirkin.
Dr. Mirkin is the Director of the International Institute for Nanotechnology, the George B. Rathmann Professor of Chemistry, Professor of Medicine, and Professor of Materials Science and Engineering at Northwestern University. He is a chemist and a world renowned nanoscience expert, who is known for his development of nanoparticle-based biodetection schemes, the invention of Dip-Pen Nanolithography, and contributions to supramolecular chemistry. He is author of over 320 manuscripts and over 325 patents (69 issued). He is the founder of two companies, Nanosphere Inc. (NASDAQ: NSPH) and NanoInk Inc., which are commercializing nanotechnology applications in the life science and semiconductor industries. He is listed as one of the top 10 most cited chemists in the world, and is the top most cited nanomedicine researcher in the world.
Professor Mirkin has been recognized for his accomplishments with over 50 national and international Awards. These include a iCON Innovator of the Year Award (2007), NIH Director’s Pioneer Award, the Collegiate Inventors Award (2002, 2004), an Honorary Doctorate Degree from Dickinson College, the Pennsylvania State University Outstanding Science Alumni Award, the ACS Nobel Laureate Signature Award for Graduate Education in Chemistry, a Dickinson College Metzger-Conway Fellowship, the 2003 Raymond and Beverly Sackler Prize in the Physical Sciences, the Feynman Prize in Nanotechnology, the Leo Hendrick Baekeland Award, Crain’s Chicago Business “40 under 40 Award,” the Discover 2000 Award for Technological Innovation, I-Street Magazine’s Top 5 List for Leading Academics in Technology, the Materials Research Society Young Investigator Award, the ACS Award in Pure Chemistry, the PLU Fresenius Award, the Harvard University E. Bright Wilson Prize, the BF Goodrich Collegiate Inventors Award, the Camille Dreyfus Teacher-Scholar Award, the Alfred P. Sloan Foundation Award, the DuPont Young Professor Award, the NSF Young Investigator Award, the Naval Young Investigator Award, the Beckman Young Investigator Award, and the Dreyfus Foundation New Faculty Award.
He is a Fellow of the American Association for the Advancement of Science and has served on the Editorial Advisory Boards of over twenty scholarly journals. At present he is a member of the Editorial Advisory Boards of Accounts of Chemical Research, Advanced Materials, Angewandte Chemie, BioMacromolecules, Macromolecular Bioscience, SENSORS, Encyclopedia of Nanoscience and Nanotechnology, Chemistry-A European Journal, Chemistry & Biology, Nanotechnology Law & Business, The Scientist, Journal of Materials Chemistry, and Journal of Cluster Science, Plasmonics. Dr. Mirkin is the founding editor of the journal Small, one of the premier international nanotechnology journals, and he has co-edited two bestselling books on the field of nanobiotechnology.
Dr. Mirkin holds a B.S. degree from Dickinson College (1986, elected into Phi Beta Kappa) and a Ph.D. degree in chemistry from the Pennsylvania State University (1989). He was an NSF Postdoctoral Fellow at the Massachusetts Institute of Technology prior to becoming a chemistry professor at Northwestern University in 1991.
About Arrowhead Research Corporation
Arrowhead Research Corporation (www.arrowheadresearch.com) (NASDAQ:ARWR) is a leading nanotechnology company commercializing new technologies in the areas of life sciences, electronics and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has five subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, fullerene anti-oxidants, carbon-based electronics and compound semiconductor materials.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our clinical studies, our ability to successfully develop and manufacture products, rapid technological change in our industry, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, and other SEC filings discuss these and other important risk factors that may affect ou business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.
Source: Arrowhead Research Corporation